Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories pediatric Nutrition Division (Similac, PediaSure, Pedialyte, EleCare) — Worldwide Revenue ($M) ($M)
Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A
Latest, FY2025
3,974
Period ended Dec 31, 2025
Change on a year earlier
-1.2%
4,023 in FY2024
History
11 years
Since FY2015
Sources
11
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Pediatric Nutrition Division (Similac, PediaSure, Pedialyte, EleCare) — Worldwide Revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3,974 | -1.2% | SEC Filing (0001628280-26-002982) ↗ |
| FY2024 | Dec 31, 2024 | 4,023 | +2.3% | SEC Filing (0001628280-25-002092) ↗ |
| FY2023 | Dec 31, 2023 | 3,934 | +13.0% | SEC Filing (0001628280-24-002009) ↗ |
| FY2022 | Dec 31, 2022 | 3,481 | -19.0% | SEC Filing (0001628280-23-001516) ↗ |
| FY2021 | Dec 31, 2021 | 4,298 | +4.1% | SEC Filing (0001104659-22-007648) ↗ |
| FY2020 | Dec 31, 2020 | 4,127 | -0.8% | SEC Filing (0001104659-21-007942) ↗ |
| FY2019 | Dec 31, 2019 | 4,161 | +1.6% | SEC Filing (0001104659-20-005717) ↗ |
| FY2018 | Dec 31, 2018 | 4,097 | +5.3% | SEC Filing (0001104659-19-002848) ↗ |
| FY2017 | Dec 31, 2017 | 3,889 | +0.2% | SEC Filing (0001104659-18-003691) ↗ |
| FY2016 | Dec 31, 2016 | 3,883 | -2.2% | SEC Filing (0001104659-17-003920) ↗ |
| FY2015 | Dec 31, 2015 | 3,970 | – | SEC Filing (0001104659-16-091861) ↗ |
Breakdown
What makes up pediatric nutrition division (similac, pediasure, pedialyte, elecare) — worldwide revenue ($m)
- Pediatric Nutrition Division (Similac, PediaSure, Pedialyte, EleCare) — Organic / Comparable Sales Growth (%)-0.7% · FY2025
- Pediatric Nutrition Division (Similac, PediaSure, Pedialyte, EleCare) — Reported Sales Growth (%)-1.2% · FY2025
- Pediatric Nutrition Division (Similac, PediaSure, Pedialyte, EleCare) — Foreign Exchange Impact on Sales Growth (%)-0.5% · FY2025
- Pediatric Nutrition Division (Similac, PediaSure, Pedialyte, EleCare) — U.S. Revenue ($M)2,158 · FY2025
- Pediatric Nutrition Division (Similac, PediaSure, Pedialyte, EleCare) — International Revenue ($M)1,816 · FY2025
- U.S. States Where Abbott Holds WIC Infant Formula Contracts (States)42 · FY2024
- Preterm Infant Formula (NEC) Lawsuits Pending in Federal & State Courts (Lawsuits)1,760 · FY2025
- Preterm Infant Formula (NEC) Litigation Reserve Balance ($M)–
Cite this data
StockData. (2026). Abbott Laboratories Pediatric Nutrition Division (Similac, PediaSure, Pedialyte, EleCare) — Worldwide Revenue ($M) ($M), annual FY2015–FY2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/nut-ped-rev-ww
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.